WHO approves first mpox diagnostic test for faster detection

The approval of this test is a significant advancement in addressing the ongoing mpox outbreaks, particularly in regions like the Democratic Republic of the Congo (DRC), where testing has been limited. As noted by the WHO, only 37% of suspected cases in the DRC have been tested this year, highlighting the urgent need for more efficient diagnostic tools. The Alinity m MPXV assay is expected to provide immediate results, thereby reducing the waiting time for patients and healthcare workers. This development comes in the wake of the WHO’s declaration of mpox as a global public health emergency for the second time in two years, prompting the agency to expedite the evaluation of diagnostic tests and other medical products to combat the virus more effectively.

Impact on Global Health

The introduction of this diagnostic test is particularly crucial for underserved regions where healthcare resources are limited. The WHO’s assistant director-general for access to medicines emphasized that increasing access to quality-assured medical products is vital for controlling the spread of mpox and protecting communities.

Current Challenges

Despite the promising introduction of the Alinity m MPXV assay, challenges remain in the fight against mpox. The disease, which spreads through human-to-human contact and contact with infected animals, has been detected in multiple African countries, resulting in over 800 deaths this year. The emergence of two strains of the virus, including a new, more infectious variant, underscores the need for continued vigilance and rapid response in public health efforts.